Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276672 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL11505412 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL1324054 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL14840112 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL5275632 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL8653866 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL23111414 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL11505299 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL5278296 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL29210034 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383443-A1 | USE OF (HETERO)POLYOXOMETALATES FOR SIMULTANEOUSLY IMPARTING ANTIMICROBIAL PROPERTIES TO A SURFACE OF A SUBSTRATE AND REDUCING THE GROWTH OF A BIOFILM ON THE SURFACE OF THE SUBSTRATE | POM Patentverwaltungs GbR (DE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093475-A1 | USE OF (HETERO)POLYOXOMETALATES FOR SIMULTANEOUSLY IMPARTING ANTIMICROBIAL PROPERTIES TO A SURFACE OF A SUBSTRATE AND REDUCING THE GROWTH OF A BIOFILM ON THE SURFACE OF THE SUBSTRATE | POM PATENTVERWALTUNGS GBR (DE) | 2017-06-08 | — | — | WO | disclosed |
| US-8697901-B2 | Synthesis of organohalosilane monomers via enhanced cleavage of direct process residue | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130172594-A1 | Synthesis of Organohalosilane Monomers Via Enhanced Cleavage of Direct Process Residue | MOMENTIVE PERFORMANCE MATERIALS INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120232285-A1 | Sulfonyl-1,2,4-triazole salts | UNIVERSITE DE MONTREAL (CA) | 2012-09-13 | — | — | US | disclosed |
| US-20110178306-A1 | Sulphonyl-1,2,4-Triazole Salts | PHOSTECH LITHIUM INC. (CA) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178306-A1 | Sulphonyl-1,2,4-Triazole Salts | TST, STS, SQOR | TSHR 2742/4885THRB 4407/4885LMNA 4855/4885 |
| US-20120232285-A1 | Sulfonyl-1,2,4-triazole salts | STS, TST, FIS1 | TSHR 1820/4885THRB 4268/4885LMNA 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.